Autopsy report · NCT05018585

A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes

“Stopped for futility.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 4 years 1 month before it stopped.
• 321 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Diamyd Medical AB

Sponsor type

Industry

Conditions

Type 1 Diabetes Mellitus

Interventions

Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®; Colecalciferol 2000 IU; Placebo

Participants

321

Sites

60

Countries

Czechia, Estonia, Germany, Hungary, Netherlands, Poland, Spain, Sweden, United States

Trials that died the same way

• Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection
  “for futility” (71% match in meaning)
• Lidocaine and Ketamine in Abdominal Surgery
  “Futility” (69% match in meaning)
• Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
  “Project was stopped due to futility” (65% match in meaning)
• Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
  “The study stopped due to futility” (65% match in meaning)
• Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents
  “due to futility” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.